LAS VEGAS, July 27, 2015 /PRNewswire/ -- EnzymeBioSystems (OTC BB: ENZB - News) announces that a preclinical methyl amooranin batch has been completed. Amooranin is the Company's lead pharmaceutical product. EnzymeBioSystems plans to seek approval for the use of methyl amooranin in the prevention of breast cancer.
"We are pleased to announce that this preclinical batch of methyl amooranin has been completed," stated Gary Rojewski, CEO of EnzymeBioSystems. He went on to say, "This batch will allow us to move forward in beginning to conduct the required toxicology rat studies for submitting an Investigational New Drug Application ("IND") to the FDA." He added, "We still need to produce a larger batch to complete the second species studies. Our initial work continues to demonstrate that methyl amooranin appears to be promising for the reduction of tumors."
"As a precautionary note, there are no assurances that the company will ever obtain an IND for this compound," stated Mr. Rojewski.
EnzymeBioSystems produces specialty enzymes and enzyme related products. Management is also currently exploring the development of OTC proprietary products.
Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The company's actual results could differ materially from those anticipated in the forward-looking statements.
Contact: Edward Zimmerman III
7575 W. Washington Ave.
Las Vegas, NV 89128